UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
EXCHANGE ACT OF 1934
 
Date of report: For the month of May 2023

Commission File Number: 001-39084
 
Innate Pharma S.A.
 (Translation of registrant's name into English)

Innate Pharma S.A.
 117 Avenue de Luminy—BP 30191
 13009 Marseille, France
 + 33 (0) 4 30 30 30
 (Address of principal executive office)
 

 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ] Form 40-F [ ]
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [  ]
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [  ]

EXHIBIT INDEX
 


Exhibit
Description
 
 

 
SIGNATURES
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 

 
 
INNATE PHARMA S.A.
 
 
 
 
 
 
Date: May 9, 2023
By:
/s/ MONDHER MAHJOUBI
 
Name:
Mondher Mahjoubi
 
Title:
Chairman of the Executive Board and Chief Executive 
    Officer

Innate Pharma (NASDAQ:IPHA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Innate Pharma Charts.
Innate Pharma (NASDAQ:IPHA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Innate Pharma Charts.